Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Selects Two Antigen Targets from Celera Genomics for Cancer Therapeutic Development

NEW YORK, April 15 (GenomeWeb News) - Celera Genomics announced yesterday that two of its antigen targets have been selected for further investigation by Abbott for cancer therapeutic development.


The targets were developed by Celera Genomics over the last year, since the company signed a collaboration agreement with Abbott to use proteomic technologies to develop cell surface antigens that could serve as cancer therapeutics.


Kathy Ordonez, president of Celera Genomics, said the agreement is "an important milestone" toward the company's goal of developing a pipeline of therapies derived from its proteomics platform.


Financial terms for the agreement were not provided.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.